GLUE
Monte Rosa Therapeutics Inc
9.90$
-3.9%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 338.6% | -3,586.9% | -591.4% | -227.8% | 212.6% | -53.6% | -149.7% | 786.6% | -1,546.7% | -887.6% | -908.6% | -213.9% | |
| – | 21.1% | 178.3% | 43.9% | 22.8% | 3.4% | 2.4% | 9.2% | 16.4% | 75.1% | 48.2% | 44.0% | 35.4% | |
| – | 46.5% | 458.0% | 95.9% | 46.5% | 7.4% | 6.2% | 21.1% | 34.2% | 154.9% | 141.3% | 132.9% | 92.4% | |
| – | 659.3% | -1,212.2% | -62.3% | -26.4% | 180.8% | -116.1% | -123.8% | 951.7% | -120.9% | 3.3% | -84.6% | 385.4% | |
| – | 19.3% | 130.1% | 43.1% | 4.3% | 0.3% | 1.9% | 7.3% | 5.1% | 27.6% | 44.4% | 73.5% | 34.4% | |
| – | 163.4% | 926.0% | -1,302.6% | 409.6% | -50.9% | -118.0% | 109.2% | 298.7% | -2,339.7% | -6,199.5% | -3,232.1% | -2,011.3% | |
| – | – | – | – | – | 0.0% | – | – | – | -12.8% | – | – | – | |
| – | 287.6% | 23.1% | 2,087.8% | 0.2% | 1.0% | 0.0% | 1.6% | 2.7% | 1,065.2% | 7,798.9% | 3,697.0% | 2,401.4% | |
| – | 788.9% | -2,664.4% | 193.7% | 182.0% | 162.6% | -171.6% | -38.9% | 1,088.0% | -2,821.1% | 712.0% | -443.7% | 176.3% | |
| – | 319.3% | -3,717.0% | -634.5% | -232.1% | 212.3% | -55.4% | -157.0% | 781.5% | -1,574.3% | -932.0% | -982.1% | -248.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.